Literature DB >> 16427047

Time course and outcome of recovery from stroke: relevance to stem cell treatment.

Sid Gilman1.   

Abstract

Stroke is the third leading cause of death in the United States after heart disease and cancer; it has an incidence of approximately 750,000 cases per year, and it is a leading cause of disability in adults. The factors predicting a poor outcome from stroke include severe initial neurological dysfunction, hypertension, cardiac arrhythmias, myocardial infarction, hypercholesterolemia, and diabetes mellitus. The armamentarium available for improvement of neurological function after stroke is currently limited to placement in specialized stroke units, optimal therapy for medical complications, and intense physical, occupational and speech rehabilitation. Despite many trials, no pharmacological intervention has been shown convincingly to improve neurological outcome. This review was undertaken to determine the appropriate time for new approaches to the therapy of stroke such as the infusion of stem cells into the central nervous system. The literature shows in large case series that functional recovery from stroke reaches a maximum level by 3-6 months after onset, and no further recovery occurs beyond this time. Nevertheless, about 80% of these patients reach their maximum function for activities of daily living within 6 weeks from onset. Initiation of a clinical trial of stem cell therapy would require demonstration of optimal clinical improvement by neurological evaluations, with no change over at least 4 weeks of observation. Accordingly, in subjects with first-ever ischemic stroke who remained neurologically unchanged from the second until the third month after the acute event, implementation of stem cell therapy would be appropriate at approximately 3 months after the stroke.

Entities:  

Mesh:

Year:  2006        PMID: 16427047     DOI: 10.1016/j.expneurol.2005.12.003

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  6 in total

1.  Altered antinociceptive efficacy of tramadol over time in rats with painful peripheral neuropathy.

Authors:  Aldric Hama; Jacqueline Sagen
Journal:  Eur J Pharmacol       Date:  2006-12-01       Impact factor: 4.432

Review 2.  Current status of cell therapies in stroke.

Authors:  Oh Young Bang
Journal:  Int J Stem Cells       Date:  2009-05       Impact factor: 2.500

3.  Smooth muscle-generated methylglyoxal impairs endothelial cell-mediated vasodilatation of cerebral microvessels in type 1 diabetic rats.

Authors:  Fadhel Alomar; Jaipaul Singh; Hee-Seong Jang; George J Rozanzki; Chun Hong Shao; Babu J Padanilam; William G Mayhan; Keshore R Bidasee
Journal:  Br J Pharmacol       Date:  2016-10-14       Impact factor: 8.739

4.  Delayed gait recovery by resolution of limb-kinetic apraxia in a chronic hemiparetic stroke patient: A case report.

Authors:  Sung Ho Jang; Dong Hyun Byun
Journal:  Medicine (Baltimore)       Date:  2022-01-28       Impact factor: 1.889

5.  Intravenous transplantation of mesenchymal stem cells preconditioned with early phase stroke serum: current evidence and study protocol for a randomized trial.

Authors:  Suk Jae Kim; Gyeong Joon Moon; Won Hyuk Chang; Yun-Hee Kim; Oh Young Bang
Journal:  Trials       Date:  2013-10-01       Impact factor: 2.279

6.  Scaffolds for Intracerebral Grafting of Neural Progenitor Cells After Cerebral Infarction: A Systematic Review.

Authors:  Laura K Cohen; Matthew B Jensen
Journal:  Arch Neurosci       Date:  2015-10-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.